Last data update: May 13, 2024. (Total: 46773 publications since 2009)
Records 1-6 (of 6 Records) |
Query Trace: Newman RD[original query] |
---|
Notes from the field: Public health response to a human immunodeficiency virus outbreak associated with unsafe injection practices - Roka Commune, Cambodia, 2016
Ijeoma UC , Sansam S , Srun S , Vannara H , Sanith S , Sopheap T , Newman RD , Gadde R , Dejana S , Hassani AS , Ly V , Drammeh B , De A , Byrd J , Bock N . MMWR Morb Mortal Wkly Rep 2018 67 (4) 135-136 Cambodians receive 0.8–5.9 therapeutic injections per person per year, one of the highest reported rates worldwide (1,2). Appropriate medical injections and infusions can be health sustaining or lifesaving; however, improper administration can have detrimental health consequences, including infectious disease transmission (3). In 2000, it was estimated that worldwide, unsafe injection and waste disposal practices account for 260,000 new human immunodeficiency virus (HIV) infections annually (3). |
The threat of artemisinin-resistant malaria
Dondorp AM , Fairhurst RM , Slutsker L , Macarthur JR , M DJg , Guerin PJ , Wellems TE , Ringwald P , Newman RD , Plowe CV . N Engl J Med 2011 365 (12) 1073-5 In the 1970s, Chinese government scientists working on a secret “Project 523” developed a new class of potent antimalarial drugs, the artemisinins or qinghaosu derivatives. In mostly unpublished work that has just been recognized by a 2011 Lasker Award to Tu Youyou, researchers in China isolated the active compounds from the plant Artemisia annua, tested them in mice, analyzed the chemical structure of the artemisinins, and demonstrated their high potency and rapid efficacy in human trials. Although they were widely used in China during the 1980s, only in the 1990s did the artemisinins come to wider global attention in the form of artemisinin-based combination therapies. Over the past decade, these highly efficacious treatments, along with other malaria-control measures, have contributed to significant reductions of the malaria burden in many areas of the world, including parts of Africa. | Together, these successes and increased funding have revived the bold aspiration to eradicate malaria. About one quarter of malaria-afflicted countries are already shifting their focus from malaria control to elimination. Past successful malaria-elimination schemes have all depended on reliable curative drugs, used in conjunction with vector-control methods. Similarly, current elimination plans rely on the long-term availability of effective antimalarial drugs — a requirement that is pivotally dependent on the efficacy of artemisinins. The artemisinin derivative artesunate has also proven to be the best drug against severe falciparum malaria. Losing the artemisinins to resistance would be a disaster for the control and treatment of malaria and would bring eradication efforts to a standstill. |
A research agenda to underpin malaria eradication
Alonso PL , Brown G , Arevalo-Herrera M , Binka F , Chitnis C , Collins F , Doumbo OK , Greenwood B , Hall BF , Levine MM , Mendis K , Newman RD , Plowe CV , Rodriguez MH , Sinden R , Slutsker L , Tanner M . PLoS Med 2011 8 (1) e1000406 The interruption of malaria transmission worldwide is one of the greatest challenges for international health and development communities. The current expert view suggests that, by aggressively scaling up control with currently available tools and strategies, much greater gains could be achieved against malaria, including elimination from a number of countries and regions; however, even with maximal effort we will fall short of global eradication. The Malaria Eradication Research Agenda (malERA) complements the current research agenda-primarily directed towards reducing morbidity and mortality-with one that aims to identify key knowledge gaps and define the strategies and tools that will result in reducing the basic reproduction rate to less than 1, with the ultimate aim of eradication of the parasite from the human population. Sustained commitment from local communities, civil society, policy leaders, and the scientific community, together with a massive effort to build a strong base of researchers from the endemic areas will be critical factors in the success of this new agenda. |
Associations between peripheral Plasmodium falciparum malaria parasitemia, human immunodeficiency virus, and concurrent helminthic infection among pregnant women in Malawi
Thigpen MC , Filler SJ , Kazembe PN , Parise ME , Macheso A , Campbell CH , Newman RD , Steketee RW , Hamel M . Am J Trop Med Hyg 2011 84 (3) 379-85 Approximately 2 billion persons worldwide are infected with schistosomiasis and soil-transmitted helminthes (STH), many in areas where endemic malaria transmission coexists. Few data exist on associations between these infections. Nested within a larger clinical trial, primigravid and secundigravid women provided blood samples for human immunodeficiency virus (HIV) testing and peripheral malaria films and stool and urine for evaluation of STH and Schistosoma spp. during their initial antenatal clinic visit. The most common parasitic infections were malaria (37.6%), S. haematobium (32.3%), and hookworm (14.4%); 14.2% of women were HIV-infected. S. haematobium infection was associated with lower malarial parasite densities (344 versus 557 parasites/muL blood; P < 0.05). In multivariate analysis, HIV and hookworm infection were independently associated with malaria infection (adjusted odds ratio = 1.9 and 95% confidence interval = 1.2-3.0 for HIV; adjusted odds ratio = 1.9 and 95% confidence interval = 1.03-3.5 for hookworm). Concurrent helminthic infection had both positive and negative effects on malaria parasitemia among pregnant women in Malawi. |
Intermittent preventive treatment in infants for the prevention of malaria in rural Western Kenya: a randomized, double-blind placebo-controlled trial
Odhiambo FO , Hamel MJ , Williamson J , Lindblade K , ter Kuile FO , Peterson E , Otieno P , Kariuki S , Vulule J , Slutsker L , Newman RD . PLoS One 2010 5 (4) e10016 BACKGROUND: Intermittent preventive treatment in infants (IPTi) with sulphadoxine-pyrimethamine (SP) for the prevention of malaria has shown promising results in six trials. However, resistance to SP is rising and alternative drug combinations need to be evaluated to better understand the role of treatment versus prophylactic effects. METHODS: Between March 2004 and March 2008, in an area of western Kenya with year round malaria transmission with high seasonal intensity and high usage of insecticide-treated nets, we conducted a randomized, double-blind placebo-controlled trial with SP plus 3 days of artesunate (SP-AS3), 3 days of amodiaquine-artesunate (AQ3-AS3), or 3 days of short-acting chlorproguanil-dapsone (CD3) administered at routine expanded programme of immunization visits (10 weeks, 14 weeks and 9 months). PRINCIPAL FINDINGS: 1,365 subjects were included in the analysis. The incidence of first or only episode of clinical malaria during the first year of life (primary endpoint) was 0.98 episodes/person-year in the placebo group, 0.74 in the SP-AS3 group, 0.76 in the AQ3-AS3 group, and 0.82 in the CD3 group. The protective efficacy (PE) and 95% confidence intervals against the primary endpoint were: 25.7% (6.3, 41.1); 25.9% (6.8, 41.0); and 16.3% (-5.2, 33.5) in the SP-AS3, AQ3-AS3, and CD3 groups, respectively. The PEs for moderate-to-severe anaemia were: 27.5% (-6.9, 50.8); 23.1% (-11.9, 47.2); and 11.4% (-28.6, 39.0). The duration of the protective effect remained significant for up to 5 to 8 weeks for SP-AS3 and AQ3-AS3. There was no evidence for a sustained beneficial or rebound effect in the second year of life. All regimens were well tolerated. CONCLUSIONS: These results support the view that IPTi with long-acting regimens provide protection against clinical malaria for up to 8 weeks even in the presence of high ITN coverage, and that the prophylactic rather than the treatment effect of IPTi appears central to its protective efficacy. |
Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials
Aponte JJ , Schellenberg D , Egan A , Breckenridge A , Carneiro I , Critchley J , Danquah I , Dodoo A , Kobbe R , Lell B , May J , Premji Z , Sanz S , Sevene E , Soulaymani-Becheikh R , Winstanley P , Adjei S , Anemana S , Chandramohan D , Issifou S , Mockenhaupt F , Owusu-Agyei S , Greenwood B , Grobusch MP , Kremsner PG , Macete E , Mshinda H , Newman RD , Slutsker L , Tanner M , Alonso P , Menendez C . Lancet 2009 374 (9700) 1533-42 BACKGROUND: Intermittent preventive treatment (IPT) is a promising strategy for malaria control in infants. We undertook a pooled analysis of the safety and efficacy of IPT in infants (IPTi) with sulfadoxine-pyrimethamine in Africa. METHODS: We pooled data from six double-blind, randomised, placebo-controlled trials (undertaken one each in Tanzania, Mozambique, and Gabon, and three in Ghana) that assessed the efficacy of IPTi with sulfadoxine-pyrimethamine. In all trials, IPTi or placebo was given to infants at the time of routine vaccinations delivered by WHO's Expanded Program on Immunization. Data from the trials for incidence of clinical malaria, risk of anaemia (packed-cell volume <25% or haemoglobin <80 g/L), and incidence of hospital admissions and adverse events in infants up to 12 months of age were reanalysed by use of standard outcome definitions and time periods. Analysis was by modified intention to treat, including all infants who received at least one dose of IPTi or placebo. FINDINGS: The six trials provided data for 7930 infants (IPTi, n=3958; placebo, n=3972). IPTi had a protective efficacy of 30.3% (95% CI 19.8-39.4, p<0.0001) against clinical malaria, 21.3% (8.2-32.5, p=0.002) against the risk of anaemia, 38.1% (12.5-56.2, p=0.007) against hospital admissions associated with malaria parasitaemia, and 22.9% (10.0-34.0, p=0.001) against all-cause hospital admissions. There were 56 deaths in the IPTi group compared with 53 in the placebo group (rate ratio 1.05, 95% CI 0.72-1.54, p=0.79). One death, judged as possibly related to IPTi because it occurred 19 days after a treatment dose, was subsequently attributed to probable sepsis. Four of 676 non-fatal hospital admissions in the IPTi group were deemed related to study treatment compared with five of 860 in the placebo group. None of three serious dermatological adverse events in the IPTi group were judged related to study treatment compared with one of 13 in the placebo group. INTERPRETATION: IPTi with sulfadoxine-pyrimethamine was safe and efficacious across a range of malaria transmission settings, suggesting that this intervention is a useful contribution to malaria control. FUNDING: Bill & Melinda Gates Foundation. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 13, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure